Literature DB >> 3501422

Comparative bactericidal activity of cefixime, carumonam, enoxacin and roxithromycin with those of other antibiotics against resistant Haemophilus influenzae including beta-lactam tolerant strains.

M G Bergeron1, G Y Lavoie, F D Boucher.   

Abstract

One hundred isolates of Haemophilus influenzae including 50 beta-lactamase producing, five ampicillin-resistant non-beta-lactamase producing and five beta-lactam tolerant strains were tested for susceptibility (MICs and MBCs) to ampicillin, aztreonam, carumonam, cefixime, cefaclor, cefamandole, cefotaxime, imipenem, enoxacin, ciprofloxacin, roxithromycin, erythromycin, chloramphenicol, and co-trimoxazole, by a microdilution broth method. Cefotaxime, enoxacin and ciprofloxacin with MIC90 and MBC90 of less than 0.03 mg/l) were the most active antimicrobial agents tested. Cefixime, carumonam, aztreonam, and co-trimoxazole (MIC90 and MBC90 less than 0.25 mg/l) showed good activity against most strains. Roxithromycin and erythromycin had limited antibacterial activity (MIC90, 8 and 4 mg/l respectively). There were no chloramphenicol-resistant strains. Five beta-lactamase-negative strains were resistant to ampicillin, cefaclor and cefamandole but susceptible to other beta-lactams tested. Different patterns of tolerance were observed: four of five tolerant strains were tolerant to ampicillin and cefamandole, three to cefixime, cefaclor and cefotaxime, one to aztreonam. One tolerant strain was a beta-lactamase producer. Two other strains were tolerant only to co-trimoxazole.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501422     DOI: 10.1093/jac/20.5.663

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].

Authors:  W Kersten; H Müsken
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  [Cefixime therapy in sinusitis].

Authors:  W Jorde; M Schata
Journal:  Infection       Date:  1990       Impact factor: 3.553

3.  In vitro activity of new antibiotics against Haemophilus influenzae.

Authors:  K Machka; H Balg; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 4.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 5.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

6.  In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae.

Authors:  P M Mendelman; L L Henritzy; D O Chaffin; K Lent; A L Smith; T L Stull; E A Wiley
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Comparative in vitro activity of cefixime against Haemophilus influenzae isolates, including ampicillin-resistant, non-beta-lactamase-producing isolates, from pediatric patients.

Authors:  J E Mortensen; S L Himes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 8.  Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.

Authors:  R N Brogden; D M Campoli-Richards
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 9.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 10.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.